MYLK inhibitors can block the invasion and adhesion of human pancreatic cancer cell lines, suggesting that targeting MYLK may be a promising therapeutic strategy for PC cell invasion and metastasis prevention (Kaneko et al. 2002). Here, MYLK is linked to pachyonychia congenita.